A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
Marijuana and its CD4 Receptors: A New HIV Treatment Strategy?
Pathway to a Cure: Cancer Drug Helps Purge HIV From Resting Cells
Life Expectancy With HIV Increases Dramatically
Undetectable Viral Load? Not Necessarily in Semen
Engineering CD8 Cells to Kill HIV in Tissues
Pathway to a Cure: Positive Results Continue for Sangamo's CCR5 Gene Therapy
Revised U.S. Guidelines: HIV Treatment is Recommended for All People Living With HIV
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailrssprint

November 12, 2007

GSK Sues Abbott Over Norvir Price Hike

GlaxoSmithKline Plc filed a lawsuit against Abbott on Friday, November 9, over the price of Norvir, a boosting agent that works in conjunction with protease inhibitors (Bloomberg.com, 11/9).

According to GSK, the comparably high price of Norvir prevents the booster from being used with other drugs, such as GSK’s Lexiva, at a competitive price point. Abbott did not however raise the price of Kaletra, their protease inhibitor that includes Norvir.

“Abbott’s anticompetitive scheme protected Kaletra against new competitors that threatened its market dominance,” GSK said in a written complaint.

The lawsuit—filed in Oakland in federal court—is one of several filed against Abbott, who quadrupled the price from $1.71 per day in 2003 to $8.57 per day. According to the Abbott Park, Illinois, pharmaceutical giant, the price increase was a way to reflect its role as a boosting agent as opposed to a stand-alone drug.

Abbott representatives call this lawsuit “frivolous” and argue that the cost of Lexiva has increased five times since 2003.

emailrssprint


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    blue_water
    New York City
    New York


    sequoiamv
    San Jose
    California


    racine
    New York
    New York


    donnyp
    liberty
    Kentucky
Click here to join POZ Personals!
Conference Coverage

19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)
Seattle, Washington
March 5 - 8, 2012


6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011)
Rome, Italy
July 17 - 20, 2011


18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
Boston, MA
February 27 - March 2, 2011


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.